Published in Can J Psychiatry on January 01, 2015
Problems from the past and prevention for the future. Can J Psychiatry (2015) 0.75
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Medication augmentation after the failure of SSRIs for depression. N Engl J Med (2006) 5.16
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med (2009) 1.91
The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry (2010) 1.74
Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression to measure treatment impact and recovery in MDD. JAMA Psychiatry (2013) 1.71
How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry (2006) 1.69
Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry (2011) 1.65
Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology (2007) 1.39
Defining and measuring functional recovery from depression. CNS Drugs (2010) 1.21
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord (2009) 1.17
The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des (2012) 1.05
Partial remission, residual symptoms, and relapse in depression. Dialogues Clin Neurosci (2008) 1.04
Clinical Outcomes in Measurement-based Treatment (Comet): a trial of depression monitoring and feedback to primary care physicians. Depress Anxiety (2012) 1.02
Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety (2009) 1.01
Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord (2011) 0.95
The STAR*D Trial: It Is Time to Reexamine the Clinical Beliefs That Guide the Treatment of Major Depression. Can J Psychiatry (2015) 0.88
Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry (2004) 0.88
Implementing standardized assessments in clinical care: now's the time. Psychiatr Serv (2009) 0.85
Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry (2015) 0.84
Overcoming the problem of diagnostic heterogeneity in applying measurement-based care in clinical practice: the concept of psychiatric vital signs. Compr Psychiatry (2011) 0.79
Using measurement-based care with patient involvement to improve outcomes in depression. Prim Care Companion CNS Disord (2013) 0.78